Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ligand Pharmaceuticals Inc. filings document the regulatory record for a Nasdaq-listed biopharmaceutical royalty aggregator with common stock trading under LGND. The company’s disclosures cover royalty portfolio economics, technology licenses, partner-product clinical and regulatory matters, operating results, milestone payments, commercial royalties, Captisol® material sales, and NITRICIL™ licensing.
Ligand’s SEC record also includes Form 8-K reports on material agreements, license-program rights, credit-agreement amendments, Regulation FD communications, capital-structure disclosures, and financial results. Proxy materials describe board matters, shareholder voting items, executive compensation, equity awards, and governance practices for the public company.
LGND filing: Notice of proposed sale under Rule 144 reporting planned dispositions of Common Stock by an insider. The excerpt lists 10b5-1 sales on 03/04/2026 for 13,423 shares and a sale on 12/12/2025 for 1,804 shares. It also shows exercises of stock options on 03/11/2026 (reported 2,405 shares) and earlier on 12/16/2025 (652 shares). The transactions are reported as planned 10b5-1 sales and option exercises; cash consideration amounts are shown for each sale row.
Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.
The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.
The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.
Ligand Pharmaceuticals director Stephen L. Sabba exercised a stock option for 2,034 common shares at $69.51 per share and on the same day sold 2,034 shares at $201.50 per share in an open-market transaction. He now directly holds 33,793 common shares.
Ligand Pharmaceuticals director John W. Kozarich reported open-market sales of company common stock. On March 2, 2026, he sold a total of 467 shares in six separate transactions under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1.
The reported weighted-average prices for these sales ranged from about $197 to $203 per share, based on detailed price ranges in the filing. After completing the transactions, Kozarich directly owned 42,720 shares of Ligand Pharmaceuticals common stock.
LGND reported a proposed sale of common stock on a Form 144 with transactions dated 03/04/2026. The filing lists an $2,741,513.52 figure and the number 19,941,141 in the header. The excerpt shows planned sales tied to an exercise of stock options of 2,073 shares on 03/04/2026 and Restricted & Performance Stock Units of 11,350 shares with an award date of 12/31/2025. The sales are shown as common stock to be sold through Morgan Stanley Smith Barney LLC.
Ligand Pharmaceuticals filed a Form S-3 shelf registration to offer up to $100,000,000 of common stock through an at-the-market sales agreement with Leerink Partners LLC. Sales may occur from time to time after the effective date and proceeds are payable to the issuer. The prospectus supplement states the company had 19,774,343 shares outstanding as of December 31, 2025. The sales agent may receive up to 3.0% of gross proceeds as compensation, and the number and timing of sales will vary with market conditions and company instructions.